Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00046683
Recruitment Status : Completed
First Posted : October 2, 2002
Last Update Posted : July 28, 2016
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company )

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : No date given
  Study Completion Date : June 2006